| March, 2004 |
|
Incorporated Oncolys BioPharma in Tokyo, Japan |
| May, 2004 |
|
First round of financing |
| August, 2004 |
|
Second round of financing |
| October, 2004 |
|
Third round of financing |
| May 2005 |
|
Telomescan was adopted by NEDO's grant in 2005 titled, "Project for R&D on Molecule Imaging Equipment. R&D of Molecule Imaging Equipment for Malignant Tumor Therapy Support."
*NEDO: New Energy and Industrial Technology Development Organization |
| February 2006 |
|
Fourth round of financing |
| March 2006 |
|
Filed an investigational new drug (IND) application for Telomelysin® with U.S. Food and Drug Administration (FDA) |
| March 2006 |
|
Fifth round of financing |
| June 2006 |
|
Concluded a joint development agreement with Sysmex Corporation to develop TelomeScan® |
| June 2006 |
|
Concluded an exclusive license agreement with Yale University, granting Oncolys global exclusive license agreement of the novel anti-HIV agent, FESTINAVIR® |
| September 2006 |
|
Sixth round of financing |
| October 2006 |
|
Seventh round of financing |
| October 2006 |
|
Obtained a patent for Telomelysin® in Japan (Patent No. 3867968) |
| October 2006 |
|
Initiated a phase I clinical trial with Telomelysin® in the US |
| September 2007 |
|
Award by Minister of Education, Culture, Sports, Science and Technology, "The 5th Japan Bio-Venture Award" |
| November 2007 |
|
Opened the Kobe Research Center |
| March 2008 |
|
Signed strategic alliance and license agreement with Medigen Biotechnology Corp. for Telomellysin® |
| March 2008 |
|
Signed strategic alliance and license agreement with Tacere Therapeutics, Inc. for OBP-701(TT-033) |
| March 2008 |
|
Eighth round of financing |
| March 2008 |
|
Filed an investigational new drug (IND) application for FESTINAVIR® Food and Drug Administration (FDA) |
| May 2008 |
|
Initiated a phase Ia clinical trial with FESTINAVIR® in the US |
| August 2008 |
|
Apply to start phase Ib clinical study for FESTINAVIR® with Agence française de sécurité sanitaire des produits de santén (AFSSAPS) |
| January 2009 |
|
Initiated a phase Ib/IIa clinical trial with FESTINAVIR® in the FRANCE |
| October 2009 |
|
Signed an exclusive worldwide licensing agreement of OBP-801 with Astellas Pharma |
| December 2010 |
|
Signed an exclusive worldwide licensing agreement of FESTINAVIR® with Bristol-Myers Squibb |
| January 2011 |
|
Terminated licensing agreement of OBP-701 due to the strategic reason |
